living.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With WOLV Looks like sideways still....Buying oppertunity IMO...
With HDVY my friends and family are in.....They buy what I buy...
$heff, you may like/love this find...EPIQ I couldnt post on your board, but though you might want to check this gem out.
You may want to revist HDVY as well...
Fell free to post this on your board if you wish. Cheers:
Another 52 week high today....
$500 mill market cap
Pays div's too... .035 a share
They Just bought a RIVAL company for $100 million CASH
http://www.bizjournals.com/kansascity/news/2011/04/04/epiq-systems-offers-100m-deal-encore.html?ana=yfcpc
80% held by institutions:
http://eresearch.fidelity.com/eresearch/evaluate/fundamentals/ownership.jhtml?stockspage=ownership&symbols=EPIQ
Ownership Summary Institutional Stock Ownership 41.2%
Institutional Mutual Fund Ownership 38.2%
Mutual Fund Ownership 4.1%
Insider Ownership 26.7%
Other 0%
Total Outstanding Shares: 35,200,972
Institutional Ownership Details Institutional Stock &
Mutual Fund Ownership: 79.4%
Shares Owned
PRICE (T.ROWE) ASSOCIATES INC 12/31/10 5.2M $75.5M 14.90%
FMR LLC 12/31/10 3.3M $47.6M 9.38%
ST. DENIS J. VILLERE & COMPANY 12/31/10 2.6M $37.7M 7.43%
INTREPID CAPITAL MANAGEMENT INC/FL 12/31/10 2.0M $29.3M 5.78%
ASHFORD CAPITAL MANAGEMENT INC. 12/31/10 1.9M $27.6M 5.45%
VANGUARD GROUP, INC. (THE) 12/31/10 1.6M $23.7M 4.68%
BlackRock Fund Advisors 12/31/10 1.5M $21.1M 4.16%
DIMENSIONAL FUND ADVISORS LP 12/31/10 1.2M $17.9M 3.54%
BlackRock Institutional Trust Company, N.A. 12/31/10 950.5K $13.7M 2.70%
BECKER CAPITAL MANAGEMENT INC. 12/31/10 918.3K $13.2M 2.61%
Mutual Fund Ownership Details Institutional Mutual Fund & Mutual Fund (No 13F Form) Ownership: 42%
Name Reporting Date Total Holdings Position Value Outstanding
Shares Owned
FIDELITY ADVISOR SMALL CAP FUND (i) 11/30/10 3.2M $46.7M 9.21%
PRICE (T.ROWE) NEW HORIZONS FUND (i) 12/31/10 2.3M $33.1M 6.53%
PRICE (T.ROWE) SMALL CAP STOCK FUND (i) 12/31/10 1.8M $25.2M 4.97%
EPIQ - Daily Candlesticks
With Epiq Float locked Breakout? :
Another 52 week high today....
$500 mill market cap
They Just bought a RIVAL company for $100 million CASH
http://www.bizjournals.com/kansascity/news/2011/04/04/epiq-systems-offers-100m-deal-encore.html?ana=yfcpc
80% held by institutions:
http://eresearch.fidelity.com/eresearch/evaluate/fundamentals/ownership.jhtml?stockspage=ownership&symbols=EPIQ
Ownership Summary Institutional Stock Ownership 41.2%
Institutional Mutual Fund Ownership 38.2%
Mutual Fund Ownership 4.1%
Insider Ownership 26.7%
Other 0%
Total Outstanding Shares: 35,200,972
Institutional Ownership Details Institutional Stock &
Mutual Fund Ownership: 79.4%
Shares Owned
PRICE (T.ROWE) ASSOCIATES INC 12/31/10 5.2M $75.5M 14.90%
FMR LLC 12/31/10 3.3M $47.6M 9.38%
ST. DENIS J. VILLERE & COMPANY 12/31/10 2.6M $37.7M 7.43%
INTREPID CAPITAL MANAGEMENT INC/FL 12/31/10 2.0M $29.3M 5.78%
ASHFORD CAPITAL MANAGEMENT INC. 12/31/10 1.9M $27.6M 5.45%
VANGUARD GROUP, INC. (THE) 12/31/10 1.6M $23.7M 4.68%
BlackRock Fund Advisors 12/31/10 1.5M $21.1M 4.16%
DIMENSIONAL FUND ADVISORS LP 12/31/10 1.2M $17.9M 3.54%
BlackRock Institutional Trust Company, N.A. 12/31/10 950.5K $13.7M 2.70%
BECKER CAPITAL MANAGEMENT INC. 12/31/10 918.3K $13.2M 2.61%
Mutual Fund Ownership Details Institutional Mutual Fund & Mutual Fund (No 13F Form) Ownership: 42%
Name Reporting Date Total Holdings Position Value Outstanding
Shares Owned
FIDELITY ADVISOR SMALL CAP FUND (i) 11/30/10 3.2M $46.7M 9.21%
PRICE (T.ROWE) NEW HORIZONS FUND (i) 12/31/10 2.3M $33.1M 6.53%
PRICE (T.ROWE) SMALL CAP STOCK FUND (i) 12/31/10 1.8M $25.2M 4.97%
EPIQ - Daily Candlesticks
With Epiq Float locked Breakout? :
Another 52 week high today....
$500 mill market cap
Pays div's too... .035 a share
They Just bought a RIVAL company for $100 million CASH
http://www.bizjournals.com/kansascity/news/2011/04/04/epiq-systems-offers-100m-deal-encore.html?ana=yfcpc
80% held by institutions:
http://eresearch.fidelity.com/eresearch/evaluate/fundamentals/ownership.jhtml?stockspage=ownership&symbols=EPIQ
Ownership Summary Institutional Stock Ownership 41.2%
Institutional Mutual Fund Ownership 38.2%
Mutual Fund Ownership 4.1%
Insider Ownership 26.7%
Other 0%
Total Outstanding Shares: 35,200,972
Institutional Ownership Details Institutional Stock &
Mutual Fund Ownership: 79.4%
Shares Owned
PRICE (T.ROWE) ASSOCIATES INC 12/31/10 5.2M $75.5M 14.90%
FMR LLC 12/31/10 3.3M $47.6M 9.38%
ST. DENIS J. VILLERE & COMPANY 12/31/10 2.6M $37.7M 7.43%
INTREPID CAPITAL MANAGEMENT INC/FL 12/31/10 2.0M $29.3M 5.78%
ASHFORD CAPITAL MANAGEMENT INC. 12/31/10 1.9M $27.6M 5.45%
VANGUARD GROUP, INC. (THE) 12/31/10 1.6M $23.7M 4.68%
BlackRock Fund Advisors 12/31/10 1.5M $21.1M 4.16%
DIMENSIONAL FUND ADVISORS LP 12/31/10 1.2M $17.9M 3.54%
BlackRock Institutional Trust Company, N.A. 12/31/10 950.5K $13.7M 2.70%
BECKER CAPITAL MANAGEMENT INC. 12/31/10 918.3K $13.2M 2.61%
Mutual Fund Ownership Details Institutional Mutual Fund & Mutual Fund (No 13F Form) Ownership: 42%
Name Reporting Date Total Holdings Position Value Outstanding
Shares Owned
FIDELITY ADVISOR SMALL CAP FUND (i) 11/30/10 3.2M $46.7M 9.21%
PRICE (T.ROWE) NEW HORIZONS FUND (i) 12/31/10 2.3M $33.1M 6.53%
PRICE (T.ROWE) SMALL CAP STOCK FUND (i) 12/31/10 1.8M $25.2M 4.97%
EPIQ - Daily Candlesticks
With HDVY...."We have now completed the Abbott clinical trial for Phase 1 and 2 of the urine prostate cancer test validation process. In addition, we have completed all clinical laboratory genomic testing on the clinical trial specimens at MD Anderson Cancer Center. We have fully analyzed the data and are pleased with the results. We have met with and submitted all of our results to Abbott for their independent analysis and are awaiting their comments. If Abbott is satisfied with these results, we expect to receive the $250,000 milestone payment for completion of Phase 1 and 2 and move on to Phase 3 and 4 as described in the FDA Submission Plan. If for some reason Abbott chooses not to move forward, we will immediately begin licensing discussions with other international IVD companies, as well as, clinical laboratories in the US, Europe and China."
"Atlantic Alpha is now exclusively trading SVM’s K-2 model and will begin offering this technology to the public via a new fund which began trading in January 2011. HDC owns a 45% equity position in SVM Capital."
Market cap: 30 million
"The Company has recorded revenue of $2,013,741 from inception through December 31, 2010."
"At December 31, 2010, the Company had $3,295,630 in cash and cash equivalents and total current liabilities of $1,079,073. Additionally, during the first quarter of 2011, we received approximately $135,156 in cash from the receipt of a final payment under the Qualified Therapeutic Development Program (“QTDP”) grant program from the United States Government. On March 30, 2011, our total cash and cash equivalents was approximately $2,500,000. "
"The Company plans to initiate its new academic/research institution licensing program in the second quarter of 2011. Universities and research institutions that have reported the use of SVMs in published reports such as academic journals and conference proceedings will be contacted and offered a paid-up license against past and future infringement of the Company’s patented technology for a nominal one-time license administrative fee plus a percentage of any revenue generated when the results of the SVM usage are licensed for commercialization. The program will begin first with admitted usages of the Company’s SVM-RFE method. To date, over 30 U.S. institutions have been identified as using RFE through review of academic publications, with many of the reported uses relating to biomarker discovery and medical diagnostics. The Company plans to expand its licensing efforts to European institutions once all formalities have been completed for validation of the recently-granted European SVM-RFE patent. The program will later be broadened to other reported uses of SVM and other technology covered by the Company’s patents."
http://www.sec.gov/Archives/edgar/data/1141788/000118811211000819/t70200_10k.htm
With HDVY... long and strong. looking good here imo
Played that one 2 in 09 it can be a cash cow...
Sterling take a peak at HDVY
all from 10k...
"We have now completed the Abbott clinical trial for Phase 1 and 2 of the urine prostate cancer test validation process. In addition, we have completed all clinical laboratory genomic testing on the clinical trial specimens at MD Anderson Cancer Center. We have fully analyzed the data and are pleased with the results. We have met with and submitted all of our results to Abbott for their independent analysis and are awaiting their comments. If Abbott is satisfied with these results, we expect to receive the $250,000 milestone payment for completion of Phase 1 and 2 and move on to Phase 3 and 4 as described in the FDA Submission Plan. If for some reason Abbott chooses not to move forward, we will immediately begin licensing discussions with other international IVD companies, as well as, clinical laboratories in the US, Europe and China."
"Atlantic Alpha is now exclusively trading SVM’s K-2 model and will begin offering this technology to the public via a new fund which began trading in January 2011. HDC owns a 45% equity position in SVM Capital."
Market cap: 30 million
"The Company has recorded revenue of $2,013,741 from inception through December 31, 2010."
"At December 31, 2010, the Company had $3,295,630 in cash and cash equivalents and total current liabilities of $1,079,073. Additionally, during the first quarter of 2011, we received approximately $135,156 in cash from the receipt of a final payment under the Qualified Therapeutic Development Program (“QTDP”) grant program from the United States Government. On March 30, 2011, our total cash and cash equivalents was approximately $2,500,000. "
"The Company plans to initiate its new academic/research institution licensing program in the second quarter of 2011. Universities and research institutions that have reported the use of SVMs in published reports such as academic journals and conference proceedings will be contacted and offered a paid-up license against past and future infringement of the Company’s patented technology for a nominal one-time license administrative fee plus a percentage of any revenue generated when the results of the SVM usage are licensed for commercialization. The program will begin first with admitted usages of the Company’s SVM-RFE method. To date, over 30 U.S. institutions have been identified as using RFE through review of academic publications, with many of the reported uses relating to biomarker discovery and medical diagnostics. The Company plans to expand its licensing efforts to European institutions once all formalities have been completed for validation of the recently-granted European SVM-RFE patent. The program will later be broadened to other reported uses of SVM and other technology covered by the Company’s patents."
http://www.sec.gov/Archives/edgar/data/1141788/000118811211000819/t70200_10k.htm
HDVY - Daily Candlesticks
Another wolv
HDVY - Daily Candlesticks
With HDVY "We have now completed the Abbott clinical trial for Phase 1 and 2 of the urine prostate cancer test validation process. In addition, we have completed all clinical laboratory genomic testing on the clinical trial specimens at MD Anderson Cancer Center. We have fully analyzed the data and are pleased with the results. We have met with and submitted all of our results to Abbott for their independent analysis and are awaiting their comments. If Abbott is satisfied with these results, we expect to receive the $250,000 milestone payment for completion of Phase 1 and 2 and move on to Phase 3 and 4 as described in the FDA Submission Plan. If for some reason Abbott chooses not to move forward, we will immediately begin licensing discussions with other international IVD companies, as well as, clinical laboratories in the US, Europe and China."
"Atlantic Alpha is now exclusively trading SVM’s K-2 model and will begin offering this technology to the public via a new fund which began trading in January 2011. HDC owns a 45% equity position in SVM Capital."
Market cap: 30 million
"The Company has recorded revenue of $2,013,741 from inception through December 31, 2010."
"At December 31, 2010, the Company had $3,295,630 in cash and cash equivalents and total current liabilities of $1,079,073. Additionally, during the first quarter of 2011, we received approximately $135,156 in cash from the receipt of a final payment under the Qualified Therapeutic Development Program (“QTDP”) grant program from the United States Government. On March 30, 2011, our total cash and cash equivalents was approximately $2,500,000. "
"The Company plans to initiate its new academic/research institution licensing program in the second quarter of 2011. Universities and research institutions that have reported the use of SVMs in published reports such as academic journals and conference proceedings will be contacted and offered a paid-up license against past and future infringement of the Company’s patented technology for a nominal one-time license administrative fee plus a percentage of any revenue generated when the results of the SVM usage are licensed for commercialization. The program will begin first with admitted usages of the Company’s SVM-RFE method. To date, over 30 U.S. institutions have been identified as using RFE through review of academic publications, with many of the reported uses relating to biomarker discovery and medical diagnostics. The Company plans to expand its licensing efforts to European institutions once all formalities have been completed for validation of the recently-granted European SVM-RFE patent. The program will later be broadened to other reported uses of SVM and other technology covered by the Company’s patents."
http://www.sec.gov/Archives/edgar/data/1141788/000118811211000819/t70200_10k.htm
"We have now completed the Abbott clinical trial for Phase 1 and 2 of the urine prostate cancer test validation process. In addition, we have completed all clinical laboratory genomic testing on the clinical trial specimens at MD Anderson Cancer Center. We have fully analyzed the data and are pleased with the results. We have met with and submitted all of our results to Abbott for their independent analysis and are awaiting their comments. If Abbott is satisfied with these results, we expect to receive the $250,000 milestone payment for completion of Phase 1 and 2 and move on to Phase 3 and 4 as described in the FDA Submission Plan. If for some reason Abbott chooses not to move forward, we will immediately begin licensing discussions with other international IVD companies, as well as, clinical laboratories in the US, Europe and China."
http://www.sec.gov/Archives/edgar/data/1141788/000118811211000819/t70200_10k.htm
getting closer and closet imo... close watch here, holding long and strong
Volume is looking good....
volume is picking up too.....
Looking good the last couple of days....
HDVY looks very very close...
Too quiet, just waiting.....
Just waiting this one out long...
The quiet is the best part of this one imo
I did see the news yesterday, this one looks like its very close to coming back to life IMO
on watch
The Pr I posted was the only thing i have located.
Also, With hdvy the test was just displayed:
http://www.genengnews.com/industry-updates/colon-cancer-detecting-blood-test-previewed-at-medica-trade-show/101032245/
Looking good today imo...
Did everyone miss what is in my other post?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60518972
Lg,
Boba
accumulating imo
Mick, with HDVY....notice the accum....
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60518058
HDVY - Daily Candlesticks
Some research notes, connect the dots 2 words w/ HDVY
epigenomics and colovantage (DGX)
I will break it down for you real quick:
HDVY + Epigenomics= agreement
http://healthdiscoverycorp.com/pr/sept19_06.html
News from epigenomics on 2/28/11 taken from below
"The mSEPT9 biomarker is at the core of the world’s first molecular diagnostic blood tests for the detection of colorectal cancer commercialized by Epigenomics (Epi proColon) and its partner Abbott Molecular (mS9) as IVD test kits in Europe and Asia/Pacific and its licensees Quest Diagnostics (ColoVantage™), ARUP Laboratories (Methylated Septin9 Test), and Warnex Laboratories (Septin9 Test) as laboratory-developed tests in the US and Canada, respectively. The tests all detect cell-free methylated DNA of the SEPT9 gene, which is indicative of the presence of colorectal cancer. "
http://www.genengnews.com/industry-updates/epigenomics-and-qiagen-sign-collaboration-agreement-in-colorectal-cancer-blood-testing/110333006/
http://www.epigenomics.com/en/Newsroom/
the keystone: notice what the big banner is on
http://www.questdiagnostics.com/
Lg,
Boba
Tasty nugget for you, connecting the dots 2 words..
I will break it down for you real quick:
HDVY+epigenomics= agreement http://healthdiscoverycorp.com/pr/sept19_06.html
News from epigenomics on 2/28/11 taken from above
"The mSEPT9 biomarker is at the core of the world’s first molecular diagnostic blood tests for the detection of colorectal cancer commercialized by Epigenomics (Epi proColon) and its partner Abbott Molecular (mS9) as IVD test kits in Europe and Asia/Pacific and its licensees Quest Diagnostics (ColoVantage™), ARUP Laboratories (Methylated Septin9 Test), and Warnex Laboratories (Septin9 Test) as laboratory-developed tests in the US and Canada, respectively. The tests all detect cell-free methylated DNA of the SEPT9 gene, which is indicative of the presence of colorectal cancer. "
http://www.genengnews.com/industry-updates/epigenomics-and-qiagen-sign-collaboration-agreement-in-colorectal-cancer-blood-testing/110333006/
http://www.epigenomics.com/en/Newsroom/
the keystone: notice what the big banner is on http://www.questdiagnostics.com/
LG,
Boba
I am in the same mind of thought...
Price action today is worth noting.. locked more in the vault...
They have been dark... COO left to form a spinoff.. Something big brewing with this MM shake imo....I loaded more today
HDVY site updated with this:
http://www.healthdiscoverycorp.com/validations.php
The Support Vector Machine is established as one of the leading approaches to pattern recognition and machine learning worldwide. In addition to their application in molecular diagnostics, SVMs are replacing neural networks in a variety of fields including engineering, information retrieval, and bioinformatics. They have received widespread notice for their ability to discover hidden relationships in datasets and have been exploited for numerous applications, including homeland security techniques, text and image classification, handwriting and speech recognition, fingerprint identification, face recognition, fraud detection and security systems, financial securities and futures prediction, image analysis, protein structure prediction, medical diagnosis and prognosis, classification of microarray gene expression data, identifying consumer purchasing patterns, personal recommendation systems, weather prediction, decryption, engine knock detection and vehicle control and monitoring, prediction of traffic variables in transportation systems, and many others.
Many commercial institutions have already incorporated SVMs into product and research applications. Industries utilizing SVM technology include large corporations within the software and computer fields, biomedical and pharmaceutical companies, and automotive, financial, and retail industries. Educational and research institutions throughout the world have successfully applied SVMs to a wide array of applications including gene and protein expression analysis, medical image analysis and mass spectrometry.
Bought a nice chuck for cheap, will continue to buy...
Very strange trading today...
Pressure building, breaking .004 could get crazy and fast
Check the maps, they have equiptment in place.
Looks like we could have some fun later today...imo